93,104 views
▽Part 2 here▽ https://bit.ly/3KIaaC4 ▼With the PIVOT app you can play without ads and in the background▼ Download the app here↓ https://app.adjust.com/1d9d9x37 <Guest> Ichikawa Mamoru Medical translator Graduated from the Department of Health Sciences, Faculty of Medicine, The University of Tokyo. Former NHK Director After serving as a visiting researcher at Stanford University in 2016, he retired from NHK in 2020. He currently serves as Director of the READYFOR Fund Development Office and Visiting Associate Professor at Hiroshima University School of Medicine. References: Morgan Stanley Research expects the market for obesity drugs to reach $77 billion by 2030. https://www.morganstanley.com/ideas/o... US Stocks (Company Quarterly Report Online) https://shikiho.toyokeizai.net/us History of insulin treatment https://www.diabetes.co.jp/dac/insulin History of Eli Lilly and Company https://www.lilly.com/jp/who-we-are/l... History of Novo Nordisk https://www.novonordisk.co.jp/about/o... Japan Diabetes Society's opinion on off-label use of GLP-1 receptor agonists and GIP/GLP-1 receptor agonists https://www.jds.or.jp/modules/importa... Japan Diabetes Society fully revises recommendations for incretin drugs https://medical.nikkeibp.co.jp/leaf/m... US FDA continues investigation into GLP-1 receptor agonists and suicidal ideation https://www.mixonline.jp/tabid55.html... <Table of contents> 0:00 Digest 1:51 The title of medical translator 4:45 Eli Lilly's breakthrough 9:06 Development from diabetes drugs 12:53 Eli Lilly's incretin research 19:15 How obesity drugs work 20:48 The risks of obesity drugs 24:20 Preview of part 2 <MC> Ryuichiro Takeshita PIVOT Chief Global Editor X @ryuichirot Email [email protected] #EliLilly #diabetes #diabetesmedicine #obesity #obesitymedicine #pivot